Where Are We Going

[1]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[2]  W. Willett,et al.  Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. , 1990, JAMA.

[3]  G A Colditz,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[4]  V. Pinn,et al.  The evolution of the Women's Health Initiative: perspectives from the NIH. , 1995, Journal of the American Medical Women's Association.

[5]  J. Manson,et al.  The primary prevention of myocardial infarction. , 1992, New England Journal of Medicine.

[6]  S. Rössner,et al.  Coronary Drug Project Research Group. , 1978, Atherosclerosis.

[7]  S. Cummings,et al.  Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.

[8]  W. Kannel,et al.  Menopause and Risk of Cardiovascular Disease: The Framingham Study , 1976 .

[9]  M. Hlatky,et al.  Attitudes of women toward hormone therapy and prevention of heart disease. , 1995, American heart journal.

[10]  D. Kritchevsky.  Drugs Affecting Lipid Metabolism , 1988, Proceedings in Life Sciences.

[11]  S. Pauker,et al.  Patient-specific decisions about hormone replacement therapy in postmenopausal women , 1997 .

[12]  J. Carson,et al.  Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.

[13]  B Rosner,et al.  A prospective study of obesity and risk of coronary heart disease in women. , 1990, The New England journal of medicine.

[14]  J. Stamler.  Clofibrate and niacin in coronary heart disease. , 1975, JAMA.

[15]  J. Manson,et al.  Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. , 1996, The New England journal of medicine.

[16]  A. Weyman,et al.  Task force 4: Training in echocardiography , 1995 .

[17]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[18]  P. Poole‐Wilson,et al.  Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease , 1993, The Lancet.

[19]  S. Reis,et al.  Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. , 1994, Circulation.

[20]  E. Beckman,et al.  Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. , 1979, Obstetrics and gynecology.

[21]  E. Barrett-Connor.  Postmenopausal estrogen and prevention bias. , 1991, Annals of internal medicine.

[22]  H. Mcgill,et al.  Hormone Receptors of the Baboon Cardiovascular System: Biochemical Characterization of Aortic and Myocardial Cytoplasmic Progesterone Receptors , 1982, Circulation research.

[23]  J. Cohn,et al.  27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. , 1996, Journal of the American College of Cardiology.

[24]  W. Kannel,et al.  Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. , 1986, American heart journal.

[25]  D. Commerce.  Statistical abstract of the United States , 1978 .

[26]  P. Greenland,et al.  In-hospital and 1-year mortality in 1,524 women after myocardial infarction. Comparison with 4,315 men. , 1991, Circulation.

[27]  D. Brambilla,et al.  A prospective study of factors affecting age at menopause. , 1990, Journal of clinical epidemiology.

[28]  D. Berman,et al.  Cardiovascular stress response and coronary artery disease: evidence of an adverse postmenopausal effect in women. , 1998, American Heart Journal.

[29]  B Rosner,et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. , 1996, The New England journal of medicine.

[30]  R. Cannon,et al.  Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. , 1997, The New England journal of medicine.

[31]  H. S. Klopfenstein,et al.  Estrogen modulates responses of atherosclerotic coronary arteries. , 1990, Circulation.

[32]  H. Schoch.  The U.S. Veterans Administration Cardiology Drug-Lipid Study: An Interim Report , 1969 .

[33]  Everett M. Rogers,et al.  Consensus Development Conference , 1984 .

[34]  D. Herrington,et al.  Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. , 1992, Journal of the American College of Cardiology.

[35]  Caroline S. Fox,et al.  Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women , 1992, Annals of Internal Medicine.

[36]  J. Manson,et al.  Prospective study of exogenous hormones and risk of pulmonary embolism in women , 1996, The Lancet.

[37]  E. Feldman,et al.  Lipids and lipoproteins , 1989 .

[38]  S. Willich,et al.  Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. , 1987, Journal of the American College of Cardiology.

[39]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[40]  Estrogen and coronary heart disease in women. , 1991 .

[41]  V. Ernster,et al.  Invited Commentary: Does Postmenopausal Hormone Therapy Cause Breast Cancer? , 1991 .

[42]  A. Gotto,et al.  CORONARY ARTERY DISEASE Association of levels of lipoprotein Lp ( a ) , plasma lipids , and other lipoproteins with coronary artery disease documented by angiography , 2022 .

[43]  E. Eaker,et al.  Trends in nonfatal coronary heart disease in the United States, 1980 through 1989. , 1993, Archives of internal medicine.

[44]  B. Psaty,et al.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.